-transparent.png){kind=logo}
Trilostane, a competitive inhibitor of the 3 beta-hydroxysteroid dehydrogenase enzyme system, has adrenal blocking activity and has been used to treat Cushing's syndrome and other disease. To investigate is effect on the normal human hypothalamic-pituitary-testicular axis, trilostane (initially 240 mg/day) was given to ten healthy adult males, the dose increasing at weekly intervals by 240 mg/day up to 960 mg/day. When chromatography was used to remove trilostane and metabolites from the assay system, serum testosterone was found to fall on trilostane therapy (P less than 0.01) and this was accompanied by a rise in LH (P less than 0.01). The responses of FSH and LH to LHRH were unaffected by treatment. It is concluded that trilostane inhibits human testicular 3 beta-hydroxysteroid dehydrogenase and male patients on trilostane should be monitored for sexual dysfunction and impairment of testicular steroidogenesis.
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
December 1982,
Clinical endocrinology,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
May 1979,
The Journal of clinical endocrinology and metabolism,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
October 1985,
Biology of reproduction,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
March 2010,
Acta physiologica (Oxford, England),
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
November 1978,
Fertility and sterility,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
January 1988,
Hormone research,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
December 1983,
The Journal of clinical endocrinology and metabolism,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
March 2022,
Endocrinology and metabolism clinics of North America,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
February 1985,
Irish medical journal,
C G Semple, and
S W Weir, and
J A Thomson, and
G H Beastall
August 1990,
International journal of sports medicine,
